Abstract
Demecolcine (Ciba), known in England as Colcemid, has, like colchicine, the power to inhibit mitosis at the metaphase stage; it does not, like urethane, intervene at all phases of cell-division. It has proved itself to be the most specific and the least toxic of the chemotherapeutic agents available for the treatment of chronic myeloid leukaemia.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAuthor information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1956 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Piney, A. (1956). The Treatment of Myeloid Leukaemia with Demecolcine (Colcemid). In: Begemann, H. (eds) Fünfter Kongress der Europäischen Gesellschaft für Hämatologie, Freiburg i. Br., 20. bis 24. September 1955 / Cinquième Congrès de la Société Européenne d’Hématologie, Freiburg i. Br., Allemagne, 20–24 Septembre 1955. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-35395-0_17
Download citation
DOI: https://doi.org/10.1007/978-3-662-35395-0_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-02063-9
Online ISBN: 978-3-662-35395-0
eBook Packages: Springer Book Archive